-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risperidone in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risperidone in Pancreatic Ductal Adenocarcinoma Drug Details: Risperidone (VAL-401) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risperidone in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risperidone in Lung Adenocarcinoma Drug Details: Risperidone (VAL-401) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Non-Small Cell Lung Cancer Drug...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risperidone in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risperidone in Lung Adenocarcinoma Drug Details: Risperidone (VAL-401) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – risperidone
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry risperidone Drug Details DLP-114 (risperidone is 6-12 month formulation) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – risperidone
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry risperidone Drug Details Risperidone (VAL-401) is under development for the treatment of metastatic non-small...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...